vs
Side-by-side financial comparison of Skyward Specialty Insurance Group, Inc. (SKWD) and Bio-Techne (TECH). Click either name above to swap in a different company.
Skyward Specialty Insurance Group, Inc. is the larger business by last-quarter revenue ($385.6M vs $295.9M, roughly 1.3× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 11.2%, a 1.6% gap on every dollar of revenue. On growth, Skyward Specialty Insurance Group, Inc. posted the faster year-over-year revenue change (26.7% vs -6.4%). Over the past eight quarters, Skyward Specialty Insurance Group, Inc.'s revenue compounded faster (20.6% CAGR vs 4.2%).
Skyward Specialty Insurance Group, Inc. is a specialty property and casualty insurance provider offering tailored coverage solutions including commercial auto, general liability, professional indemnity, and specialty property policies. It primarily serves small-to-medium enterprises and niche industry segments across the United States, focusing on underwriting complex, hard-to-place risks for underserved client groups.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
SKWD vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $385.6M | $295.9M |
| Net Profit | $43.2M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 14.2% | 18.4% |
| Net Margin | 11.2% | 12.8% |
| Revenue YoY | 26.7% | -6.4% |
| Net Profit YoY | 200.1% | 68.3% |
| EPS (diluted) | $1.03 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $385.6M | $295.9M | ||
| Q3 25 | $382.5M | — | ||
| Q2 25 | $319.9M | $317.0M | ||
| Q1 25 | $328.5M | $316.2M | ||
| Q4 24 | $304.4M | $297.0M | ||
| Q3 24 | $300.9M | $289.5M | ||
| Q2 24 | $279.9M | $306.1M | ||
| Q1 24 | $265.0M | $303.4M |
| Q4 25 | $43.2M | $38.0M | ||
| Q3 25 | $45.9M | — | ||
| Q2 25 | $38.8M | $-17.7M | ||
| Q1 25 | $42.1M | $22.6M | ||
| Q4 24 | $14.4M | $34.9M | ||
| Q3 24 | $36.7M | $33.6M | ||
| Q2 24 | $31.0M | $40.6M | ||
| Q1 24 | $36.8M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 14.2% | 18.4% | ||
| Q3 25 | 15.8% | — | ||
| Q2 25 | 15.6% | -7.5% | ||
| Q1 25 | 15.7% | 12.2% | ||
| Q4 24 | 6.1% | 16.0% | ||
| Q3 24 | 15.6% | 13.8% | ||
| Q2 24 | 14.4% | 15.0% | ||
| Q1 24 | 17.7% | 22.1% |
| Q4 25 | 11.2% | 12.8% | ||
| Q3 25 | 12.0% | — | ||
| Q2 25 | 12.1% | -5.6% | ||
| Q1 25 | 12.8% | 7.1% | ||
| Q4 24 | 4.7% | 11.7% | ||
| Q3 24 | 12.2% | 11.6% | ||
| Q2 24 | 11.1% | 13.3% | ||
| Q1 24 | 13.9% | 16.2% |
| Q4 25 | $1.03 | $0.24 | ||
| Q3 25 | $1.10 | — | ||
| Q2 25 | $0.93 | $-0.11 | ||
| Q1 25 | $1.01 | $0.14 | ||
| Q4 24 | $0.33 | $0.22 | ||
| Q3 24 | $0.89 | $0.21 | ||
| Q2 24 | $0.75 | $0.26 | ||
| Q1 24 | $0.90 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $168.5M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $1.0B | $2.0B |
| Total Assets | $4.8B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $168.5M | $172.9M | ||
| Q3 25 | $160.1M | — | ||
| Q2 25 | $136.6M | $162.2M | ||
| Q1 25 | $112.9M | $140.7M | ||
| Q4 24 | $121.6M | $177.5M | ||
| Q3 24 | $105.6M | $187.5M | ||
| Q2 24 | $73.0M | $152.9M | ||
| Q1 24 | $85.1M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $1.0B | $2.0B | ||
| Q3 25 | $961.4M | — | ||
| Q2 25 | $899.9M | $1.9B | ||
| Q1 25 | $850.7M | $2.0B | ||
| Q4 24 | $794.0M | $2.1B | ||
| Q3 24 | $797.5M | $2.1B | ||
| Q2 24 | $723.6M | $2.1B | ||
| Q1 24 | $692.3M | $2.0B |
| Q4 25 | $4.8B | $2.5B | ||
| Q3 25 | $4.6B | — | ||
| Q2 25 | $4.3B | $2.6B | ||
| Q1 25 | $4.0B | $2.6B | ||
| Q4 24 | $3.7B | $2.7B | ||
| Q3 24 | $3.6B | $2.7B | ||
| Q2 24 | $3.4B | $2.7B | ||
| Q1 24 | $3.2B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $408.1M | — |
| Free Cash FlowOCF − Capex | $402.6M | — |
| FCF MarginFCF / Revenue | 104.4% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 9.44× | — |
| TTM Free Cash FlowTrailing 4 quarters | $755.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $408.1M | — | ||
| Q3 25 | $171.4M | — | ||
| Q2 25 | $88.2M | $98.2M | ||
| Q1 25 | $96.8M | $41.1M | ||
| Q4 24 | $305.1M | $84.3M | ||
| Q3 24 | $168.0M | $63.9M | ||
| Q2 24 | $21.0M | $75.5M | ||
| Q1 24 | $94.3M | $81.0M |
| Q4 25 | $402.6M | — | ||
| Q3 25 | $168.9M | — | ||
| Q2 25 | $87.1M | $93.3M | ||
| Q1 25 | $96.6M | $31.0M | ||
| Q4 24 | $300.9M | $77.5M | ||
| Q3 24 | $167.6M | $54.7M | ||
| Q2 24 | $18.4M | $57.5M | ||
| Q1 24 | $94.0M | $64.5M |
| Q4 25 | 104.4% | — | ||
| Q3 25 | 44.2% | — | ||
| Q2 25 | 27.2% | 29.4% | ||
| Q1 25 | 29.4% | 9.8% | ||
| Q4 24 | 98.8% | 26.1% | ||
| Q3 24 | 55.7% | 18.9% | ||
| Q2 24 | 6.6% | 18.8% | ||
| Q1 24 | 35.5% | 21.3% |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.1% | 3.2% | ||
| Q4 24 | 1.4% | 2.3% | ||
| Q3 24 | 0.1% | 3.2% | ||
| Q2 24 | 0.9% | 5.9% | ||
| Q1 24 | 0.1% | 5.4% |
| Q4 25 | 9.44× | — | ||
| Q3 25 | 3.73× | — | ||
| Q2 25 | 2.27× | — | ||
| Q1 25 | 2.30× | 1.82× | ||
| Q4 24 | 21.18× | 2.42× | ||
| Q3 24 | 4.58× | 1.90× | ||
| Q2 24 | 0.68× | 1.86× | ||
| Q1 24 | 2.56× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SKWD
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
